Do you want to read an article? Please log in or register.
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Gastrointestinal Cancer
COMMENTED
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Gastrointestinal Cancer
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
JAMA Oncol.
Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J
doi: 10.1001/jamaoncol.2020.2814.
Gastrointestinal Cancer
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Lancet Oncol
Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan AC, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely SC, Moser BA, Oliveira JM, Carlesi R, Walgren RA, Oh DY
doi: 10.1016/S1470-2045(21)00409-5
Gastrointestinal Cancer
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
J Clin Oncol
Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, Perrier H, Dahan L, Bourgeois V, Akouz FK, Soularue E, Ly VL, Molin Y, Lecomte T, Ghiringhelli F, Coriat R, Louafi S, Neuzillet C, Manfredi S, Malka D, PRODIGE 38 AMEBICA Investigators/Collaborators.
doi: 10.1200/JCO.21.00679
Gastrointestinal Cancer
A Randomized Phase 2 Study Of Nivolumab Monotherapy Or Nivolumab Combined with Ipilimumab In Patients with Advanced Gastrointestinal Stromal Tumors
Clin Cancer Res
Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, Hagopian A, Andes R, Sauer L, Brackert SR, Chow W, DeMatteo R, Eilber FC, Glaspy JA, Chmielowski B
doi: 10.1158/1078-0432.CCR-21-0878
Gastrointestinal Cancer
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Lancet Oncol.
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA
doi: 10.1016/S1470-2045(20)30321-1.
Gastrointestinal Cancer
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
JAMA Oncol.
Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ
doi: 10.1001/jamaoncol.2019.0270.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Eur J Cancer.
Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R, Paz-Ares L, Duchnowska R, Garcia MA, Isla D, Jassem J, Appel W, Milanowski J, Van Meerbeeck JP, Wolf J, Li A, Acevedo A, Popat S
doi: 10.1016/j.ejca.2019.11.019.
RECOMMENDED
Lung, Respiratory and Thoracic CancerCOVID-19
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Clarke JM, Patel JD, Robert F, Kio EA, Thara E, Ross Camidge D, Dunbar M, Nuthalapati S, Dinh MH, Bach BA
doi: 10.1016/j.lungcan.2021.09.004